Published in J Immunol on July 01, 1975
Specific immune lysis of paramyxovirus-infected cells by H-2-compatible thymus-derived lymphocytes. Immunology (1976) 1.81
Cells that express viral antigens but lack H-2 determinants are not lysed by immune thymus-derived lymphocytes but are lysed by other antiviral immune attack mechanisms. Proc Natl Acad Sci U S A (1976) 1.17
Cell-mediated cytotoxicity to herpes-infected cells in humans: dependence on antibodies. Infect Immun (1977) 1.11
Lymphocyte cytotoxicity to influenza virus-infected cells: response to vaccination and virus infection. Infect Immun (1978) 1.00
Effector cell involved in cell-mediated cytotoxicity to cells infected with herpes simplex virus type 1. Infect Immun (1977) 0.88
Immune effector cell activity in canines: failure to demonstrate genetic restriction in direct antiviral cytotoxicity. Infect Immun (1978) 0.87
Leukocyte cytotoxicity in a persistent virus infection: presence of direct cytotoxicity but absence of antibody-dependent cellular cytotoxicity in horses infected with equine infectious anemia virus. Infect Immun (1979) 0.83
Cell-mediated cytotoxicity against murine cells infected with 6/94 virus, a parainfluenza type 1 isolate from multiple sclerosis brain tissue. Infect Immun (1976) 0.78
Natural cytotoxic cell activity linked to time of recurrence of herpes labialis. Clin Exp Immunol (1984) 0.75
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med (1966) 5.97
Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A (1990) 5.05
Precipitation of radioactively labeled samples: a semi-automatic multiple-sample processor. Cell Immunol (1972) 3.35
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol (1986) 3.12
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Human T-cell clones recognize chemically synthesized peptides of influenza haemagglutinin. Nature (1982) 2.84
Congenital rubella. Clinicopathologic, virologic, and immunologic studies. Am J Dis Child (1965) 2.82
Isolation of cDNA clones encoding the 20K non-glycosylated polypeptide chain of the human T-cell receptor/T3 complex. Nature (1986) 2.76
B-lymphocyte heterogeneity: development and characterization of an alloantiserum which distinguishes B-lymphocyte differentiation alloantigens. J Exp Med (1977) 2.44
Pseudomonas colonization in cystic fibrosis. A study of 160 patients. JAMA (1978) 2.42
Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 2.41
Comparison of latex agglutination with established bacteriological tests for diagnosis of cerebrospinal meningitis. Lancet (1989) 2.38
Antigen-specific human T lymphocyte clones: induction, antigen specificity, and MHC restriction of influenza virus-immune clones. J Immunol (1982) 2.30
Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg (1974) 2.22
Mistyping ACE heterozygotes. PCR Methods Appl (1993) 2.19
Herpesvirus hominis types I and II: a specific microindirect hemagglutination test. Proc Soc Exp Biol Med (1970) 2.11
Impaired in vitro cell-mediated immunity to rubella virus during pregnancy. N Engl J Med (1973) 2.06
A 51 Cr microassay technique for cell-mediated immunity to viruses. J Immunol (1973) 1.91
Effect of murine cytomegalovirus on the in vitro responses of T and B cells to mitogens. J Immunol (1976) 1.84
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum (1996) 1.83
Immunoglobulins in serum and nasal secretions following infection with type 1 parainfluenza virus and injection of inactivated vaccines. J Immunol (1967) 1.79
Mixed leukocyte stimulation of normal peripheral leukocytes by autologous lymphoblastoid cells. Science (1970) 1.79
Respiratory syncytial virus neutralizing activity in nasal secretions following natural infection. Proc Soc Exp Biol Med (1969) 1.79
Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol (1999) 1.69
Theta-sensitive cell and erythropoiesis: identification of a defect in W/Wv anemic mice. Science (1977) 1.67
Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor. Exp Hematol (1991) 1.62
Leukotrienes augment interleukin 1 production by human monocytes. J Immunol (1985) 1.55
In vitro stimulation of murine spleen cells using a microculture system and a multiple automated sample harvester. J Immunol Methods (1973) 1.54
Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol (1997) 1.53
Cellular immune responses to Herpes simplex virus type 1 in recurrent herpes labialis: in vitro blastogenesis and cytotoxicity to infected cell line. J Infect Dis (1975) 1.50
Antigen-specific human T lymphocyte clones: viral antigen specificity of influenza virus-immune clones. J Immunol (1982) 1.49
An antigenic marker for human thymic lymphocytes. J Immunol (1973) 1.46
Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ (1979) 1.43
Isolation from man of "avian infectious bronchitis virus-like" viruses (coronaviruses) similar to 229E virus, with some epidemiological observations. J Infect Dis (1969) 1.41
Human mixed lymphocyte cultures. Evaluation of a microculture technique utilizing the Multiple Automated Sample Harvester (MASH). Clin Exp Immunol (1973) 1.41
Differential effectiveness of complement fixed by IgG and IgM antibodies in the cytolysis of dog kidney tissue culture cells. Immunology (1966) 1.41
Role of food allergy in serous otitis media. Ann Allergy (1994) 1.40
Nutrition factors in relation to cellular and regulatory immune variables in a free-living elderly population. Am J Clin Nutr (1990) 1.39
Specific murine B-cell activation by synthetic single-and double-stranded polynucleotides. J Exp Med (1973) 1.37
CSF-1 deficiency in the op/op mouse has differential effects on macrophage populations and differentiation stages. Exp Hematol (1992) 1.37
Familial thymic aplasia. Attempted reconstitution with fetal thymus in a Millipore diffusion chamber. N Engl J Med (1972) 1.37
Asbestos fibers and silica particles stimulate rat alveolar macrophages to release tumor necrosis factor. Autoregulatory role of leukotriene B4. Am Rev Respir Dis (1989) 1.35
Demonstration of a blocking factor in the plasma and spinal fluid of patients with subacute sclerosing panencephalitis. I. Partial characterization. J Exp Med (1974) 1.35
In vitro synergism between interferons and human lymphotoxin: enhancement of lymphotoxin-induced target cell killing. J Immunol (1983) 1.35
Studies of cell-mediated immunity to measles virus by in vitro lymphocyte-mediated cytotoxicity. J Infect Dis (1974) 1.34
Glomerular microtubules of systemic lupus erythematosus. Lancet (1970) 1.33
Antibody responses in serum and nasal secretions of children immunized with inactivated and attenuated measles-virus vaccines. N Engl J Med (1969) 1.32
Blastogenic response of Toxoplasma-infected mouse spleen cells to T- and B-cell mitogens. Clin Exp Immunol (1975) 1.31
Ideal target organism for quantitative bactericidal assays. Infect Immun (1978) 1.31
Maturation of the rabbit alveolar macrophage during animal development. III. Phagocytic and bactericidal functions. Pediatr Res (1977) 1.31
Lymphocyte activation in subacute sclerosing panencephalitis virus and cytomegalovirus infections. In vitro stimulation in response to viral-infected cell lines. J Exp Med (1973) 1.30
Use of microculture plates and the multiple automated sample harvester for in vitro microassay of bacterial toxins. Appl Microbiol (1974) 1.30
In vitro influenza virus-specific antibody production in man: antigen-specific and HLA-restricted induction of helper activity mediated by cloned human T lymphocytes. J Immunol (1982) 1.29
Viral investigations in ulcerative colitis and regional enteritis. Gastroenterology (1973) 1.27
Specific impairment of cell-mediated immunity in mothers of infants with congenital infection due to cytomegalovirus. J Infect Dis (1977) 1.26
Increased susceptibility of males to infection. Lancet (1969) 1.25
Plasma and spinal-fluid blocking factor in SSPE. N Engl J Med (1973) 1.23
Development of specific cellular and humoral immune responses in children immunized with live rubella virus vaccine. J Infect Dis (1974) 1.22
Asbestos exposure and retention as determinants of airway disease and asbestos alveolitis. Am Rev Respir Dis (1986) 1.21
Use of cryopreserved virus-infected target cells in a lymphocytotoxicity 51Cr release microassay for cell-mediated immunity to cytomegalovirus. Infect Immun (1976) 1.20
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer (1995) 1.19
Depressed specific cell-mediated immunity to Herpes simplex virus type 1 in patients with recurrent herpes labialis. Infect Immun (1975) 1.18
Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum (1995) 1.18
Bursting atlantal fracture associated with rupture of the transverse ligament. J Bone Joint Surg Am (1970) 1.17
Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol (1997) 1.16
Human T-cell heterogeneity as delineated with a specific human thymus lymphocyte antiserum. In vitro effects on mitogen response mixed leukocyte culture, cell-mediated lymphocytotoxicity, and lymphokine production. J Clin Invest (1975) 1.16
Platelet-activating factor (PAF-acether) enhances the concomitant production of tumour necrosis factor-alpha and interleukin-1 by subsets of human monocytes. Immunology (1991) 1.16
Age-dependent susceptibility of neonatal rats to group B streptococcal type III infection: correlation of severity of infection and response of myeloid pools. Infect Immun (1982) 1.16
Biologic significance of the secretory A immunoglobulins. Pediatrics (1971) 1.16
Identification of functional platelet-activating factor receptors on human keratinocytes. J Invest Dermatol (1995) 1.15
Enhancement of Pseudomonas aeruginosa lung clearance after local immunization with a temperature-sensitive mutant. Infect Immun (1983) 1.14
Solitary bone cyst: treatment with freeze-dried cancellous bone allograft. A study of one hundred seventy-seven cases. J Bone Joint Surg Am (1969) 1.14
You Can Control Asthma: evaluation of an asthma education program for hospitalized inner-city children. Patient Educ Couns (1991) 1.14
Effect of chemotactins released by Staphylococcus aureus and Pseudomonas aeruginosa on the murine respiratory tract. Infect Immun (1985) 1.14
Lithium toxicity in a newborn. Pediatrics (1971) 1.14
PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol (2000) 1.14
Congenital anaemia after transplacental B19 parvovirus infection. Lancet (1994) 1.13
Establishment of a human fetal cardiac myocyte cell line. In Vitro Cell Dev Biol (1991) 1.13
Pulmonary inflammation and fibrosis in a murine model of asbestosis and silicosis. Possible role of tumor necrosis factor. Inflammation (1989) 1.13
Surface antigens on Schistosoma mansoni. II. Adsorption of a Forssman-like host antigen by schistosomula. Clin Exp Immunol (1972) 1.12
Platelet-activating factor (PAF) enhances tumor necrosis factor production by alveolar macrophages. Prevention by PAF receptor antagonists and lipoxygenase inhibitors. J Immunol (1989) 1.12